The DOI matches its Crossref record; 48 of the 49 references it cites were found in a registry or an index.
Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes
Open accessAbstract
Given its critical role in T-cell signaling, interleukin-2-inducible kinase (ITK) is an appealing therapeutic target that can contribute to the pathogenesis of certain infectious, autoimmune, and neoplastic diseases. Ablation of ITK subverts Th2 immunity, thereby potentiating Th1-based immune responses. While small-molecule ITK inhibitors have been identified, none have demonstrated clinical utility. Ibrutinib is a confirmed irreversible inhibitor of Bruton tyrosine kinase (BTK) with outstanding clinical activity and tolerability in B-cell malignancies. Significant homology between BTK and ITK alongside in silico docking studies support ibrutinib as an immunomodulatory inhibitor of both ITK and BTK. Our comprehensive molecular and phenotypic analysis confirms ITK as an irreversible T-cell target of ibrutinib. Using ibrutinib clinical trial samples along with well-characterized neoplastic (chronic lymphocytic leukemia), parasitic infection (Leishmania major), and infectious disease (Listeria monocytogenes) models, we establish ibrutinib as a clinically relevant and physiologically potent ITK inhibitor with broad therapeutic utility. This trial was registered at www.clinicaltrials.gov as #NCT01105247 and #NCT01217749.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although ibrutinib inhibits other similar kinases that contain C481, including ITK and BLK,7,22”
From Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib (2014) · cites this paper as [22]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“At relapse, none of the patients had mutations in other kinases containing a cysteine residue homologous to C481 in BTK that are irreversibly inhibited by ibrutinib”
From Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib (2014) · cites this paper as [22]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“mutations have not been observed in these other targets, findings that suggest that BTK is its critical target.”
From Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib (2014) · cites this paper as [22]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Honigberg, L. A., Smith, A. M., Sirisawad, M., Verner, E., Loury, D., Chang, B., Li, S., Pan, Z., Thamm, D. H., Miller, R. A., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1004594107 · Cited by 1,561
Self-citationAdvani, R. H., Buggy, J. J., Sharman, J. P., Smith, S. M., Boyd, T. E., Grant, B., Kolibaba, K. S., Furman, R. R., Rodriguez, S., Chang, B. Y., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.7906 · Cited by 1,128 · cited 1×
“Irreversible ITK binding, ITK signal inhibition, and Th1-skewed cytokine patterns were also identified in CLL patients treated with ibrutinib in 2 clinical trials.(37,38) These findings were validated using a well-established mouse model of cutaneous leishmaniasis, and further clinical relevance was demonstrated using…”
BackgroundSelf-citationHerman, S. E. M., Gordon, A. L., Hertlein, E., Ramanunni, A., Zhang, X., Jaglowski, S., Flynn, J., Jones, J., Blum, K. A., Buggy, J. J., et al. (2011) · Blood · doi:10.1182/blood-2011-01-328484 · Cited by 807
Self-citationLong-term Outcome of 525 Patients With Mycosis Fungoides and Sézary Syndrome
Kim, Y. H., Liu, H. L., Mraz‐Gernhard, S., Varghese, A., & Hoppe, R. T. (2003) · Archives of Dermatology · doi:10.1001/archderm.139.7.857 · Cited by 652
Ramsay, A. G., Johnson, A. J., Lee, A. M., Görgün, G., Dieu, R. L., Blum, W. G., Byrd, J. C., & Gribben, J. G. (2008) · Journal of Clinical Investigation · doi:10.1172/jci35017 · Cited by 619
Self-citationMarks, D. I., Paietta, E. M., Moorman, A. V., Richards, S. M., Buck, G. A. N., Dewald, G. W., Ferrando, A. A., Fielding, A. K., Goldstone, A. H., Ketterling, R. P., et al. (2009) · Blood · doi:10.1182/blood-2009-08-231217 · Cited by 420
The B-cell receptor signaling pathway as a therapeutic target in CLL
Woyach, J. A., Johnson, A. J., & Byrd, J. C. (2012) · Blood · doi:10.1182/blood-2012-02-362624 · Cited by 412
Self-citationRequirement for Tec Kinases Rlk and Itk in T Cell Receptor Signaling and Immunity
Schaeffer, E. M., Debnath, J., Yap, G. S., McVicar, D. W., Liao, X. C., Littman, D. R., Sher, A., VARMUS, H. E., Lenardo, M. J., & Schwartzberg, P. L. (1999) · Science · doi:10.1126/science.284.5414.638 · Cited by 398
TEC FAMILY KINASES IN T LYMPHOCYTE DEVELOPMENT AND FUNCTION
Berg, L. J., Finkelstein, L. D., Lucas, J. A., & Schwartzberg, P. L. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104743 · Cited by 341
Liu, K., Bunnell, S. C., Gurniak, C. B., & Berg, L. J. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.187.10.1721 · Cited by 337
Cited by
Sorted by citations
Items 501–600 of 813
Ogunleye, F. N., Glick, A., Stender, M., & Jaiyesimi, I. A. (2015) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2015.11.011 · Cited by 10
Spotlight on Ibrutinib in PCNSL: Adding Another Feather to Its Cap
Lakshmanan, A., & Byrd, J. C. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0714 · Cited by 10
Self-citationZorn, C. N., Simonowski, A., & Huber, M. (2018) · Scientific Reports · doi:10.1038/s41598-018-33769-1 · Cited by 10
Orthosteric and allosteric modulation of human kinases A mechanistic view
Mathur, P. (2020) · Frontiers in bioscience · doi:10.2741/4864 · Cited by 10
Potential strategies against resistance to CAR T-cell therapy in haematological malignancies
Cai, Q., Zhang, M., & Li, Z. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920962963 · Cited by 10
Yang, S., Zhu, R., Li, N., Feng, Y., Zuo, R. M., Gale, R. P., & Huang, X. (2021) · Acta Haematologica · doi:10.1159/000518398 · Cited by 10
Xu, B., Liu, X., & Gao, S.-H. (2021) · Drug Development Research · doi:10.1002/ddr.21884 · Cited by 10
Arresting the Inflammatory Drive of Chronic Lymphocytic Leukemia with Ibrutinib
Bachireddy, P., & Wu, C. J. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-3106 · Cited by 10
T Cell Defects and Immunotherapy in Chronic Lymphocytic Leukemia
Vlachonikola, E., Σταματόπουλος, Κ., & Chatzidimitriou, A. (2021) · Cancers · doi:10.3390/cancers13133255 · Cited by 10
Relapse of Hodgkin lymphoma after autologous transplantation
Jethava, Y. S., Murthy, G. S. G., & Hamadani, M. (2017) · Hematology/Oncology and Stem Cell Therapy · doi:10.1016/j.hemonc.2016.12.002 · Cited by 9
The safety of Bruton’s tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemia
Tran, P. N., & O'Brien, S. M. (2017) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2017.1344213 · Cited by 9
Perincheri, S. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.719140 · Cited by 9
The Immunomodulatory Functions of BTK Inhibition in the Central Nervous System
Cao, T., Wang, Z., & Zhu, X. (2022) · Journal of Inflammation Research · doi:10.2147/jir.s389958 · Cited by 10
Suzuki, T., Miyakoshi, S., Nanba, A., Uchiyama, T., Kawamoto, K., & Aoki, S. (2018) · Journal of the Japan Society of the Reticuloendothelial System · doi:10.3960/jslrt.18012 · Cited by 9
Iskierka‐Jazdzewska, E., & Robak, T. (2019) · Expert Review of Hematology · doi:10.1080/17474086.2020.1696185 · Cited by 9
Promises and pitfalls of targeted agents in chronic lymphocytic leukemia
Lew, T. E., Anderson, M. A., & Seymour, J. F. (2020) · Cancer Drug Resistance · doi:10.20517/cdr.2019.108 · Cited by 9
Contribution of the TIM-3/Gal-9 immune checkpoint to tropical parasitic diseases
Bailly, C. (2022) · Acta Tropica · doi:10.1016/j.actatropica.2022.106792 · Cited by 9
Hanel, W. G., Shindiapina, P., Bond, D. A., Sawalha, Y., Epperla, N., Voorhees, T. J., Welkie, R. L., Huang, Y., Behbehani, G. K., Zhang, X., et al. (2023) · Cancers · doi:10.3390/cancers15051437 · Cited by 9
Self-citationRationale for the combination of venetoclax and ibrutinib in T-prolymphocytic leukemia
Kornauth, C., Herbaux, C., Boidol, B., Guillemette, C., Caron, P., Mayerhoefer, M. E., Poulain, S., Tournilhac, O., Pemovska, T., Chong, S. J. F., et al. (2021) · Haematologica · doi:10.3324/haematol.2020.271304 · Cited by 9
Ex vivo drug responses and molecular profiles of 597 pediatric acute lymphoblastic leukemia patients
Enblad, A. P., Krali, O., Gezelius, H., Lundmark, A., Blom, K., Andersson, C. R., Palle, J., Frost, B., Ryhänen, S. J., Flægstad, T., et al. (2025) · HemaSphere · doi:10.1002/hem3.70176 · Cited by 8
Two targets for the price of one
Ansell, S. M. (2013) · Blood · doi:10.1182/blood-2013-08-518548 · Cited by 8
Chronic Lymphocytic Leukemia: Exploiting Vulnerabilities with Targeted Agents
Maly, J. J., & Blachly, J. S. (2016) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-016-0299-0 · Cited by 8
Neurotoxicity of Tumor Immunotherapy: The Emergence of Clinical Attention
Zhang, B., Li, X., Yin, T., Qin, D., Chen, Y., Ma, Q., Shu, P., & Wang, Y. (2022) · Journal of Oncology · doi:10.1155/2022/4259205 · Cited by 8
Management of CAR T-cell Related Toxicities
Murthy, H. S., Yassine, F., Iqbal, M., Alotaibi, S., Moustafa, M. A., & Kharfan‐Dabaja, M. A. (2022) · Hematology/Oncology and Stem Cell Therapy · doi:10.56875/2589-0646.1029 · Cited by 8
Corneal Melt Associated With Cancer Immunotherapy
Hsu, J., Dixit, L., Jhanji, V., & Ahmad, S. (2023) · Cornea Open · doi:10.1097/coa.0000000000000005 · Cited by 8
Treatment Response in Individual Organs Affected by Chronic Graft-Versus-Host Disease
Morishita, T., Martin, P. J., & Inamoto, Y. (2025) · Cells · doi:10.3390/cells14040238 · Cited by 8
Demitrovičová, Ĺ., MIKUSKOVA, E., Oravcová, I., Cingelová, S., Drgoňa, Ľ., & Mladosievičová, B. (2017) · Neoplasma · doi:10.4149/neo_2017_320 · Cited by 8
Atypical primary cutaneous cryptococcosis during ibrutinib therapy for chronic lymphocytic leukemia
Peri, A. M., Rossio, R., Tafuri, F., Benzecry, V., Grancini, A., Reda, G., Bandera, A., & Peyvandi, F. (2019) · Annals of Hematology · doi:10.1007/s00277-019-03837-1 · Cited by 8
Lapčík, P., Pospisilova, A., Janáčová, L., Grell, P., Fabián, P., & Bouchal, P. (2020) · Cancers · doi:10.3390/cancers12092638 · Cited by 8
The role of BTK inhibitors on the tumor microenvironment in CLL
McCay, J., & Gribben, J. G. (2022) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2022.2064995 · Cited by 8
Palaniyandi, S., Strattan, E., Kumari, R., Mysinger, M., Hakim, N., Kesler, M., Apatira, M., Bittencourt, F. M., Wang, L., Jia, Z. J., et al. (2023) · Bone Marrow Transplantation · doi:10.1038/s41409-023-02001-8 · Cited by 8
PD-L1 blockade: rejuvenating T cells in CLL
Kater, A. P., & van der Windt, G. J. W. (2015) · Blood · doi:10.1182/blood-2015-05-638338 · Cited by 8
Fiorcari, S., Atene, C. G., Maffei, R., Debbia, G., Potenza, L., Luppi, M., & Marasca, R. (2021) · Haematologica · doi:10.3324/haematol.2020.277392 · Cited by 8
Maggioni, G., Fedrigo, M., Visentin, A., Carturan, E., Ruocco, V., Trentin, L., Alaibac, M., & Angelini, A. (2023) · Current Oncology · doi:10.3390/curroncol30090599 · Cited by 7
Shree, T., Haebe, S., Czerwinski, D. K., Eckhert, E., Day, G., Sathe, A., Grimes, S. M., Frank, M. J., Maeda, L. S., Alizadeh, A. A., et al. (2023) · Blood Advances · doi:10.1182/bloodadvances.2023011589 · Cited by 7
Azizuddin, S., Kazi, M., Nadaf, A., Hasan, N., Husain, A., Kesharwani, P., & Ahmad, F. J. (2024) · Process Biochemistry · doi:10.1016/j.procbio.2024.04.002 · Cited by 7
Mauro, F. R., Frustaci, A. M., Visentin, A., Vitale, C., Bartoletti, M., Oltolini, C., Zappulo, E., & Mikulska, M. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104408 · Cited by 7
Poole, A., Girard, N., Clayton, F. C., & Tantravahi, S. K. (2016) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2016.1243679 · Cited by 7
Mamand, S., Carr, M., Allchin, R. L., Ahearne, M. J., & Wagner, S. D. (2019) · Blood Advances · doi:10.1182/bloodadvances.2018027821 · Cited by 7
Targeted Agents in the Treatment of Indolent B-Cell Non-Hodgkin Lymphomas
Minson, A. G., Tam, C. S. L., Dickinson, M. J., & Seymour, J. F. (2022) · Cancers · doi:10.3390/cancers14051276 · Cited by 8
Zhang, J., Liao, D., Chen, R., Zhu, F., Ma, Y., Gao, L., Qu, G., Cui, C., Sun, Z., Lei, X., et al. (2022) · Angewandte Chemie · doi:10.1002/ange.202201908 · Cited by 7
Cellular Therapy in High-Risk Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter Syndrome
Barbanti, M. C., Appleby, N., Kesavan, M., & Eyre, T. A. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.888109 · Cited by 7
Zhang, J., Cai, D., Gao, R., Miao, Y., Cui, Y., Liu, Z., Zhang, H., Yan, X., & Su, N. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1307242 · Cited by 7
Leveraging Cancer Therapeutics for the HIV Cure Agenda: Current Status and Future Directions
Polizzotto, M. N., Chen, G. L., Tressler, R. L., & Godfrey, C. C. (2015) · Drugs · doi:10.1007/s40265-015-0426-6 · Cited by 7
Quinquenel, A., de Fontbrune, F. S., Durot, É., Pannetier, M., Michonneau, D., Socié, G., Delmer, A. J., & de Latour, R. P. (2016) · British Journal of Haematology · doi:10.1111/bjh.14029 · Cited by 7
Emerging treatment options for the management of Hodgkin's lymphoma: clinical utility of Nivolumab
Bond, D. A., & Alinari, L. (2017) · Journal of Blood Medicine · doi:10.2147/jbm.s117452 · Cited by 7
Argyropoulos, K. V., & Palomba, M. L. (2018) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2018.05.012 · Cited by 7
Repurposing Food and Drug Administration–Approved Drugs to Promote Antitumor Immunity
Sukhatme, V. V., Ramalingam, S. S., Ahmed, R., & Sukhatme, V. P. (2019) · The Cancer Journal · doi:10.1097/ppo.0000000000000368 · Cited by 7
Targeted Treatment of Follicular Lymphoma
Nath, K., & Gandhi, M. K. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11020152 · Cited by 7
Yin, Q., Sivina, M., Robins, H., Yusko, E. C., Vignali, M., O'Brien, S., Keating, M. J., Ferrajoli, A., Estrov, Z. E., Jain, N., et al. (2018) · immuneACCESS · doi:10.21417/b77g6v · Cited by 7
Loganathan, T., & Doss, C. G. P. (2025) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2025.1510896 · Cited by 6
The clinical safety of ibrutinib in chronic lymphocytic leukemia
Molica, S. (2015) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2015.1084286 · Cited by 6
Real-world management of targeted therapies in chronic lymphocytic leukemia
Weis, T. M., Gutierrez, J., Kabel, C. C., King, A. C., Daley, R. J., & Stump, S. E. (2022) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552221090869 · Cited by 6
Yu, X., Qiu, S., Sun, D., Guo, P., & Li, Q. (2022) · Molecules · doi:10.3390/molecules27217451 · Cited by 6
Ibrutinib-Related Uveitis in Non-Hodgkin Lymphoma Patients: A Case Report and Literature Review
Mendez, R., Pineda-Sierra, J. S., Romero-Santos, S., Cifuentes‐González, C., Bonaccorso, S., Couto, C. A., Schlaen, A., Mejía‐Salgado, G., & de‐la‐Torre, A. (2024) · Ocular Immunology and Inflammation · doi:10.1080/09273948.2023.2295540 · Cited by 6
Xing, Y., Zhao, K., Zhang, Y., & Wang, Y. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1463505 · Cited by 6
Molica, S. (2017) · Expert Review of Hematology · doi:10.1080/17474086.2017.1313108 · Cited by 6
Sato, R., Jacob, J., & Gaballa, S. R. (2017) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2017.1387907 · Cited by 6
Deng, G., He, J., Huang, Q., Li, T., Huang, Z., Gao, S., Xu, J., Wang, T., & Di, J. (2023) · Cancers · doi:10.3390/cancers15082356 · Cited by 6
Lu, Y., Liu, H.-G., Ye, S., Zhou, L., Luo, X., Dang, X. Y., Yuan, X., Qian, W., Liang, A., & Li, P. (2023) · PubMed Central · doi:10.3760/cma.j.issn.0253-2727.2023.10.004 · Cited by 6
Richter transformation—is there light at the end of this tunnel?
Eyre, T. A. (2023) · Hematology · doi:10.1182/hematology.2023000442 · Cited by 6
Therapeutic targeting of microenvironment in follicular lymphoma
Nowakowski, G. S., & Ansell, S. M. (2014) · Hematology · doi:10.1182/asheducation-2014.1.169 · Cited by 6
Harrop, S., Polliack, A., & Tam, C. S. L. (2020) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2020.1849682 · Cited by 6
Ye, X., Liu, M., Lv, C., Li, Y., Chen, L., Zhang, J., Mu, J., & Deng, Q. (2022) · Technology in Cancer Research & Treatment · doi:10.1177/15330338221133224 · Cited by 6
Wang, S., Zhu, Y., Qian, X., Ding, T., Yuan, Y., Li, Y., Wu, H., & Chen, T. (2023) · Advances in Clinical and Experimental Medicine · doi:10.17219/acem/159288 · Cited by 6
Drug repurposing: Ibrutinib exhibits immunosuppressive potential in organ transplantation
Zhang, Q., Chen, J., Gao, H., Zhang, S., Zhao, C., Zhou, C., Wang, C., Li, Y., Cai, Z., & Mou, L. (2018) · International Journal of Medical Sciences · doi:10.7150/ijms.24460 · Cited by 6
Ibrutinib and Pyoderma Gangrenosum in a Patient With B-Cell Chronic Lymphocytic Leukemia
Biondo, G., Ibatici, A., Sola, S., Brunasso, A. M. G., & Massone, C. (2019) · American Journal of Dermatopathology · doi:10.1097/00000372-900000000-98182 · Cited by 6
Current advances in Hodgkin's lymphoma
Vadakara, J., & Andrick, B. J. (2019) · Chronic Diseases and Translational Medicine · doi:10.1016/j.cdtm.2019.02.003 · Cited by 6
Progress in Chronic Lymphocytic Leukemia with Targeted Therapy
Wilson, W. H. (2016) · New England Journal of Medicine · doi:10.1056/nejme1515235 · Cited by 6
Barton, J. C., Bertoli, L. F., & Cavender, J. B. (2025) · Cureus · doi:10.7759/cureus.77872 · Cited by 5
Hematopoietic stem cell gene therapy for the treatment of X-linked agammaglobulinemia
Luthers, C. R., Mittelhauser, A., Colamartino, A., Xiaomeng, W., Cirigliano, S., Long, J. D., Sanchez, J. M., Romero, Z. G., & Kohn, D. B. (2025) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2025.101555 · Cited by 5
Impact of ibrutinib on inflammation in a mouse model of Graves’ orbitopathy
Kim, C., Park, J. H., Choi, Y. J., Jun, H. O., Chung, J. K., Park, T. K., Yoon, J. S., Yang, J. W., & Jang, S. Y. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1420024 · Cited by 5
Anti-CD19 CAR T-cell therapy for primary and secondary CNS lymphomas
Losi, G., Mussetti, A., Peña, M., López‐Pereira, P., Sureda, A. M., & Novelli, S. (2024) · Bone Marrow Transplantation · doi:10.1038/s41409-024-02496-9 · Cited by 5
Advances in Bruton tyrosine kinase (Btk) inhibition are steered by Bruton tyrosine kinase phylogeny
Minotti, G., Camilli, M., Salvatorelli, E., & Menna, P. (2025) · British Journal of Pharmacology · doi:10.1111/bph.17466 · Cited by 5
Ibrutinib: better combined with other drugs?
Ghia, P. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70388-2 · Cited by 5
B cell receptor pathway in chronic lymphocytic leukemia: specific role of CC-292
Brown, J. R., & Arnason, J. E. (2014) · ImmunoTargets and Therapy · doi:10.2147/itt.s37419 · Cited by 5
Allchin, R. L., Kelly, M. E., Mamand, S., Doran, A., Keane, T., Ahearne, M. J., & Wagner, S. D. (2019) · PLoS ONE · doi:10.1371/journal.pone.0215765 · Cited by 5
The future of antibody therapy in chronic lymphocytic leukemia
Crombie, J. L., & Brown, J. R. (2021) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2021.1966414 · Cited by 5
Emerging new cell therapies/immune therapies in B-cell non-Hodgkin's lymphoma
Banerjee, T., & Vallurupalli, A. (2021) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2021.100825 · Cited by 5
Response Challenges to Cancer Immunotherapies
Al-Janabi, I. I. (2022) · Al-Rafidain Journal of Medical Sciences · doi:10.54133/ajms.v2i.65 · Cited by 5
Targeted Therapy for Chronic Lymphocytic Leukemia: Current Status and Future Directions
Arnason, J. E., & Brown, J. R. (2015) · Drugs · doi:10.1007/s40265-014-0338-x · Cited by 5
Winqvist, M., Palma, M., Heimersson, K., Mellstedt, H., Österborg, A., & Lundin, J. (2017) · British Journal of Haematology · doi:10.1111/bjh.14836 · Cited by 5
A case of inflammatory myopathy in graft vs host disease - A potential role for ibrutinib
Wilkinson, M. C., Yeung, D. T. O., & Limaye, V. S. (2021) · Neuromuscular Disorders · doi:10.1016/j.nmd.2021.06.015 · Cited by 5
Li, C., Fan, C., Lü, S., Qiu, Q., Gao, X., Yan, X., Wang, S., Zhao, B., Liu, X., Song, Y., et al. (2022) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.2c00709 · Cited by 5
la Garza‐Salazar, F. D., Colunga-Pedraza, P. R., Coronado-Alejandro, E., Gutiérrez‐Aguirre, C. H., Cantú‐Rodríguez, O. G., & Gómez‐Almaguer, D. (2023) · British Journal of Haematology · doi:10.1111/bjh.18712 · Cited by 5
Hosier, G. W., & Touma, N. J. (2017) · Canadian Urological Association Journal · doi:10.5489/cuaj.4316 · Cited by 5
Autoimmune myelitis in a CLL patient undergoing treatment with ibrutinib
Wanner, D., Bohn, J., Rudzki, J. D., Stockhammer, G., & Steurer, M. (2018) · Annals of Hematology · doi:10.1007/s00277-018-3381-y · Cited by 5
Ibrutinib in the management of Waldenstrom macroglobulinemia
Yosef, A., Touloukian, E. Z., & Nambudiri, V. E. (2018) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155218786037 · Cited by 5
Novel therapies targeting cutaneous T cell lymphomas and their microenvironment
Reneau, J. C., & Wilcox, R. A. (2021) · Seminars in Hematology · doi:10.1053/j.seminhematol.2021.02.002 · Cited by 5
Differential regulation of CTLA4 expression through BTK-dependent and independent mechanisms in CLL
Yano, M., Nunes, J. J., Mo, X. M., Rogers, K. A., Woyach, J. A., Byrd, J. C., & Muthusamy, N. (2022) · Blood Advances · doi:10.1182/bloodadvances.2021005571 · Cited by 6
Self-citationReceptors of immune cells mediates recognition for tumors
Anang, V., Singh, A., Kottarath, S. K., & Verma, C. (2022) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2022.09.009 · Cited by 5
Chen, S., & Chiorazzi, N. (2023) · Hematological Oncology · doi:10.1002/hon.3144 · Cited by 5
Autoimmune cytopenia and CLL ride together
Moreno, C. (2021) · Blood · doi:10.1182/blood.2021010944 · Cited by 5
Bruton Tyrosine Kinase Degraders in B-Cell Malignancies
Huynh, T., Rodrı́guez, S., & Danilov, A. V. (2024) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-23-0520 · Cited by 4
Shmidt, D. I., & Mamonkin, M. (2024) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2024.05.018 · Cited by 4
Understanding and Managing Infectious Complications in Chronic Lymphocytic Leukemia
Vainer, N., Katsimigas, A., Rotbain, E. C., & Niemann, C. U. (2025) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2025.05.003 · Cited by 4
Advances in treatment of chronic graft-versus-host disease
Morishita, T., & Inamoto, Y. (2025) · International Journal of Hematology · doi:10.1007/s12185-025-04102-0 · Cited by 4
Ibrutinib-associated oral ulcers
Thermos, G., & Tosios, K. I. (2019) · Oral Oncology · doi:10.1016/j.oraloncology.2019.104445 · Cited by 4
Fisch, S. C., Tuscano, J. M., Qi, L., & Jonas, B. A. (2022) · Leukemia Research · doi:10.1016/j.leukres.2022.106947 · Cited by 4
Autoimmune cytopenias in chronic lymphocytic leukemia: a growing challenge in targeted therapies?
Tryc-Szponder, J., Joks, M., & Gil, L. (2022) · Acta Haematologica Polonica · doi:10.5603/ahp.a2022.2042 · Cited by 4
Metadata
- Authors
- Dubovsky, J. A., Beckwith, K. A., Natarajan, G., Woyach, J. A., Jaglowski, S., Zhong, Y., Hessler, J. D., Liu, T.-M., Chang, B. Y., Larkin, K. M., Stefanovski, M. R., Chappell, D. L., Frissora, F. W., Smith, L. L., Smucker, K. A., Flynn, J. M., Jones, J. A., Andritsos, L. A., Maddocks, K., Lehman, A. M., Furman, R., Sharman, J., Mishra, A., Caligiuri, M. A., Satoskar, A. R., Buggy, J. J., Muthusamy, N., Johnson, A. J., & Byrd, J. C.
- Affiliations
- Department of Internal Medicine, Division of Hematology,
- The Ohio State University (US)
- Pharmacyclics (United States) (US)
- Weill Cornell Medicine (US)
- Willamette Valley Cancer Institute and Research Center (US)
- Department of Pathology, and
- ORCID
- Beckwith, Kyle A.
- Natarajan, Gayathri
- Woyach, Jennifer A.
- Jaglowski, Samantha
- Chang, Betty Y.
- Chappell, Danielle L.
- Smith, Lisa L.
- Flynn, Joseph M.
- Jones, Jeffrey A.
- Andritsos, Leslie A.
- Maddocks, Kami
- Furman, Richard
- Sharman, Jeff
- Mishra, Anjali
- Caligiuri, Michael A.
- Satoskar, Abhay R.
- Muthusamy, Natarajan
- Johnson, Amy J.
- Byrd, John C.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2013-10-10
- Volume
- 122
- Issue
- 15
- Pages
- 2539-2549
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- PMC
- PMC3795457
- OpenAlex
- W2089103836
- Cited by
- 810
- References
- 49
- Citations by year
- 2026: 30 · 2025: 43 · 2024: 55 · 2023: 51 · 2022: 70 · 2021: 98 · 2020: 68 · 2019: 71 · 2018: 71 · 2017: 70 · 2016: 65 · 2015: 67 · 2014: 43 · 2013: 5
- FWCI
- 29.54
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Blood (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (4p01ca081534-16)
- National Cancer Institute (P01CA095426, P50CA140158, T32CA009338, 5 T32 CA009338-33-03, P30CA016058, K12CA133250, P01-CA-081534)
- Topics
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Keywords
- ibrutinib, irreversible kinase inhibitors, Bruton's tyrosine kinase, T cell signaling, Th1 response, Th2 immune response, chronic lymphocytic leukemia, Leishmania major, Listeria monocytogenes, immunomodulation
- MeSH terms
- Adenine, Animals, Disease Models, Animal, Enzyme Inhibitors, Humans, Leukemia, Listeriosis, Lymphocyte Activation, Piperidines, Protein-Tyrosine Kinases, Pyrazoles, Pyrimidines, Leishmaniasis, Cutaneous, CD8-Positive T-Lymphocytes, Th1 Cells, Th2 Cells, Jurkat Cells, Mice, Primary Cell Culture
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
